Actively Recruiting
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases Registry and Biorepository
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2021-09-09
252
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
M
McGill University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and autoimmune myositis, involve immune system dysregulation that can lead to lung damage known as interstitial lung disease (ILD). This research aims to better understand the clinical, pathological, laboratory, and imaging features of SARD patients with lung involvement to identify unique characteristics and discover new disease mechanisms and potential treatment targets. The study will also address important clinical questions about predicting ILD development, disease progression, and treatment options in SARD patients. The study involves creating a longitudinal registry and biorepository of patients diagnosed with ILD-SARDs. Participants will provide clinical data, including medical history, imaging, pulmonary function tests, and treatment details, collected at every visit. Biological samples such as blood, serum, DNA/RNA, and excess biopsy tissues (skin, lung, muscle, bronchoalveolar lavage) will be collected and stored for future research. Blood samples from treatment-naive patients will be used for advanced genetic and immune cell analysis, and samples from others will be processed and biobanked. This setup supports future studies on disease mechanisms and potential therapies. Participants will be regularly assessed through clinical evaluations, questionnaires on symptoms and quality of life, and routine tests. The study will monitor outcomes like survival, lung transplant rates, acute exacerbations, hospitalizations, and patient-reported measures over five years. Medical oversight includes physical exams, adverse event monitoring, and laboratory result reviews. The research enables national and international collaboration to improve understanding and management of ILD in SARD patients, with an expected study duration extending to 2026.
CONDITIONS
Brief Title
ILD-SARDs Registry and Biorepository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be aged 18 years or older
- Diagnosis of interstitial lung disease confirmed by a chest CT scan
- Diagnosis of a systemic autoimmune rheumatic disease, undifferentiated connective tissue disease, or features of autoimmunity
- Willing and able to provide informed consent and follow study procedures
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are followed longitudinally with annual clinical assessments and data collection, including medical history, imaging, pulmonary function tests, and questionnaires to track the progression of interstitial lung disease and systemic autoimmune rheumatic diseases.
Annual visits and additional visits as needed
Duration - Up to 5 years
At each visit, participants provide biological samples such as blood draws, and when available, excess tissue from biopsies or bronchoalveolar lavage fluid is collected for biobanking to support future research.
Blood draws at each visit; additional sample collection when clinically available
Trial Site Locations
Total: 1 location
1
RI-MUHC
Montreal, Quebec, Canada, H3G 1A4
Actively Recruiting
Research Team
D
Deborah Assayag, MD, MAS
V
Victoria Nam-Amnath, RN, BScN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here